Skip to main content

Table 6 Third line therapies after failure of Docetaxel/Oxaliplatin treatment

From: DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma

Third line therapy (n = 15)
Treatment Number of Patients Percent
Gemcitabine + Capecitabine 8 53.3
5-FU/Oxaliplatin based 3 20
5-FU/Irinotecan based 4 26.7
  1. 5-FU/Oxaliplatin based (OFF, FUFOX, XELOX, FOLFOX); 5-FU/Irinotecan based (XELIRI, FOLFIRI)